Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.

doi:10.1182/bloodadvances.2023010779

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.

Blood advances - 26 Sept 2023

Russler-Germain David A, Krysiak Kilannin, Ramirez Cody, Mosior Matthew, Watkins Marcus P, Gomez Felicia, Skidmore Zachary L, Trani Lee, Gao Feng, Geyer Susan, Cashen Amanda F, Mehta-Shah Neha, Kahl Brad S, Bartlett Nancy L, Alderuccio Juan P, Lossos Izidore S, Ondrejka Sarah L, Hsi Eric D, Martin Peter, Leonard John P, Griffith Malachi, Griffith Obi L, Fehniger Todd A

Abstract excerpt

Follicular lymphoma (FL) is clinically heterogeneous, with select patients tolerating extended watch-and-wait, whereas others require prompt treatment, suffer progression of disease within 24 months of treatment (POD24), and/or experience aggressive histologic transformation (t-FL). Because our understanding of the relationship between genetic alterations in FL and patient outcomes remains limited, we conducted a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic factors in colorectal cancer

Share to Lymphoma Diagnosis and Treatment

Share to Lymphoma, Follicular

Share to Mutation

Share to Prognosis

Share to Progression-Free Survival

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 37493986
DOI: 10.1182/bloodadvances.2023010779
PMCID: PMC10514406

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.PMID 37493986Read ↗

Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors.Semantic proximity Read ↗

Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.Semantic proximity Read ↗

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016Semantic proximity Read ↗

From genetics to the clinic: a translational perspective on follicular lymphoma.Semantic proximity Read ↗

Advances in the multi-omics landscape of follicular lymphomaSemantic proximity Read ↗

Identification of genetic subtypes in follicular lymphoma.Semantic proximity Read ↗

Molecular subclusters of follicular lymphoma: a report from the United Kingdom's Haematological Malignancy Research Network.Semantic proximity Read ↗

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.Semantic proximity Read ↗

Decreased Expression of T-Cell-Associated Immune Markers Predicts Poor Prognosis in Patients with Advanced Follicular Lymphoma Received Rituximab Plus BendamustineSemantic proximity Read ↗

Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.Semantic proximity Read ↗

Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.Semantic proximity Read ↗

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.